Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Global survey reveals top workforce concerns, evolving strategic priorities, and key technology investment areas for life sciences manufacturers
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme
Phase 3 study results will form the basis for future discussions with global regulatory authorities
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
Subscribe To Our Newsletter & Stay Updated
